Short: From Obesity Drug to Risk Strategy - Why Captives Need to Rethink GLP-1s
Unable to add items
Sorry, we're unable to add the item because your cart is already full.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Failed to remove from Wish List.
Please try again later
Adding to library failed
Please try again
Unable to follow podcast
Unable to unfollow podcast
Short: From Obesity Drug to Risk Strategy - Why Captives Need to Rethink GLP-1s
-
Narrated by:
-
By:
In this GCP Short, produced in partnership with MAXIS Global Benefits Network, we explore findings from the network's latest whitepaper on GLP-1s, often known as weight-loss drugs.
Dr Leena Johns, chief health & wellness officer at MAXIS GBN and author of the whitepaper, joins Richard to discuss the evolving demand and understanding of GLP-1s and why captives are perfectly suited to support employer's in implementing a global GLP-1 strategy.
Read the full whitepaper here.
More information and register for Global Benefits Congress, in London, on 22 October, here.
adbl_web_anon_alc_button_suppression_t1
No reviews yet